H1N1 Infection – Pipeline Review, H1 2012Global Markets DirectMarch 19, 2012 162 Pages - SKU: GMD3811070 |
|
The World Market for Pain Management Drugs and Devices
5/20/2013 | published by: Kalorama Information
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and
|
read more...
|
$3,500.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
5/15/2013 | published by: GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players”. The report is a vital source of up-to-date information with
|
read more...
|
$2,995.00
|
|
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is
|
read more...
|
$3,495.00
|
|
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is
|
read more...
|
$3,495.00
|
|
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is
|
read more...
|
$3,495.00
|
|
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is
|
read more...
|
$3,495.00
|
|
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is
|
read more...
|
$3,495.00
|
|
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease
5/14/2013 | published by: GBI Research
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease Summary GBI Research’s report “Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI)
|
read more...
|
$3,500.00
|
|
EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022
5/15/2013 | published by: GlobalData
EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022 Summary Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani
|
read more...
|
$3,995.00
|
|
Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is
|
read more...
|
$3,495.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Infectious Diseases Reports